MHLW Approves Additional Indications For Sanofi’s Taxotere And Designates Pfizer’s Selzentry An Orphan Drug
This article was originally published in PharmAsia News
Executive Summary
The second division on drugs of the Ministry of Health, Labor and Welfare's Pharmaceutical and Food Sanitation Council approved July 31 additional indications of treating prostate cancer to Sanofi Aventis' Taxotere (docetaxel), mycobacterium avium complex to Taisho Pharmaceutical's Clarith (clarithromycin)and Abbott Japan's Klacid (clarithromycin). The committee also designated Pfizer's HIV drug Selzentry (maraviroc) an orphan drug. (Click here for more - Japanese language